September 27, 2005

Cell Therapeutics lung cancer drug helps women

NEW YORK (Reuters) - Cell Therapeutics Inc. on Tuesday said
a mid-stage trial of it experimental lung cancer drug showed a
significant survival benefit for women, sending its shares
soaring more than 40 percent.

In the recently completed study, Cell Therapeutics said the
35 women with advanced non-small cell lung cancer who received
its Xyotax plus the chemotherapy carboplatin had a 36 percent
probability of living at least one year.

The was a statistically significant survival benefit over
both the men in the study and those receiving just
chemotherapy, the Seattle-based biotechnology company said at a
presentation in New York.

Only 16 percent of the 39 men receiving the same regimen
survived the deadly, difficult-to-treat disease for at least
one year.

"To the best of our knowledge this is the first time a drug
therapy for advanced lung cancer has consistently demonstrated
such a strong survival advantage for women compared to men or
compared to women randomized to treatment with standard
chemotherapy," the company's chief medical officer, Jack
Singer, said in a statement.

The company had previously reported that women treated with
Xyotax survived significantly longer than women treated with
the standard chemotherapy.

Shares of Cell Therapeutics were up 92 cents, or 43
percent, to $3.04 on Nasdaq, where they were the day's highest
percentage gainer.